LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Free Cash Flow data on file, last reported at -$33.6 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 107.82% year-over-year to -$33.6 million in Q1 2026; TTM through Mar 2026 was -$86.6 million, a 66.26% decrease from a year earlier, with the FY2025 full-year figure at -$69.2 million, down 15.55% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$33.6 million, down from -$32.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for LENZ reached as high as -$9.2 million in Q3 2025 and fell as low as -$33.6 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$18.7 million across 5 years, with a median of -$16.2 million in 2025.
• Across the five-year window, Free Cash Flow soared 56.0% in 2024 and tumbled 249.37% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$23.4 million in 2022, then advanced by 10.58% to -$21.0 million in 2023, then surged by 56.0% to -$9.2 million in 2024, then tumbled by 249.37% to -$32.2 million in 2025, then decreased by 4.17% to -$33.6 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$33.6 million in Q1 2026, -$32.2 million in Q4 2025, and -$9.2 million in Q3 2025.